Scarica l'app Stockscreener
9.14
2.45%
-0.23
Dopo l'orario di chiusura:
9.05
-0.09
-0.98%
Precedente Chiudi:
$9.37
Aprire:
$9.26
Volume 24 ore:
1.71M
Relative Volume:
1.41
Capitalizzazione di mercato:
$568.13M
Reddito:
$2.00M
Utile/perdita netta:
$-43.51M
Rapporto P/E:
-6.8133
EPS:
-1.3415
Flusso di cassa netto:
$-39.73M
1 W Prestazione:
-1.08%
1M Prestazione:
-16.83%
6M Prestazione:
+71.80%
1 anno Prestazione:
+27.65%
Intervallo 1D:
$8.88
$9.38
Intervallo di 1 settimana:
$8.88
$10.93
Portata 52W:
$4.50
$11.45
Sagimet Biosciences Inc Stock (SGMT) Company Profile
Nome
Sagimet Biosciences Inc
Settore
Industria
Telefono
(650) 561-8600
Indirizzo
155 BOVET RD., SUITE 303, SAN MATEO
Compare SGMT vs VRTX, MRNA, REGN, ARGX, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
SGMT
Sagimet Biosciences Inc
|
9.14 | 574.35M | 2.00M | -43.51M | -39.73M | -1.3415 |
VRTX
Vertex Pharmaceuticals Inc
|
504.73 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
190.01 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
735.20 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
919.21 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
206.64 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Sagimet Biosciences Inc Stock (SGMT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-26 | Iniziato | Rodman & Renshaw | Buy |
| 2026-02-03 | Iniziato | Guggenheim | Buy |
| 2026-01-28 | Iniziato | Barclays | Equal Weight |
| 2025-08-11 | Iniziato | Wedbush | Outperform |
| 2025-08-07 | Ripresa | H.C. Wainwright | Buy |
| 2025-07-24 | Iniziato | Canaccord Genuity | Buy |
| 2024-12-06 | Iniziato | Oppenheimer | Outperform |
| 2024-11-12 | Iniziato | UBS | Buy |
| 2024-06-28 | Downgrade | Goldman | Buy → Neutral |
| 2024-05-02 | Iniziato | H.C. Wainwright | Buy |
| 2024-03-25 | Iniziato | Leerink Partners | Outperform |
| 2023-08-08 | Iniziato | Goldman | Buy |
| 2023-08-08 | Iniziato | JMP Securities | Mkt Outperform |
| 2023-08-08 | Iniziato | Piper Sandler | Overweight |
| 2023-08-08 | Iniziato | TD Cowen | Outperform |
Mostra tutto
Sagimet Biosciences Inc Borsa (SGMT) Ultime notizie
Sagimet closes $115 million stock offering for drug development By Investing.com - Investing.com Canada
Sagimet Biosciences Announces Closing of Underwritten Offering of Series A Common Stock and Pre-Funded Warrants - GlobeNewswire
Cantor Fitzgerald reiterates Sagimet stock rating on acne trial data By Investing.com - Investing.com Canada
Citizens cuts Sagimet Biosciences stock price target on trial data - Investing.com
Clear Street Maintains Sagimet Biosciences(SGMT.US) With Buy Rating, Maintains Target Price $28 - Moomoo
Oppenheimer raises Sagimet stock price target on acne trial data - Investing.com
Why is Sagimet Biosciences stock rallying today? By Investing.com - Investing.com Canada
Why Is Sagimet Biosciences Stock Trading Higher Today?Sagimet Biosciences (NASDAQ:SGMT) - Benzinga
Sagimet Biosciences Shares Rise 12% After Denifanstat Phase 3 Acne Trial Data - Yahoo Finance
Sagimet stock surges on positive acne trial data - Investing.com
Stock sales through Leerink are suspended at Sagimet Biosciences (SGMT). - Stock Titan
Sagimet Raises $115M At Premium To Fund Phase 3 Acne Drug Trial – SGMT Stock Surges Pre-Market - Yahoo Finance
Sagimet Reports 52-Week Denifanstat Acne Trial Results - grafa.com
Sagimet Prices $115 Million Offering of Series A Shares, Warrants; Shares Rise Pre-Bell - Yahoo Finance
Sagimet reports 52-week acne trial data, plans U.S. study - Investing.com
Sagimet prices $115 million stock offering at $10 per share By Investing.com - Investing.com South Africa
Sagimet prices $115 million stock offering at $10 per share - Investing.com
Sagimet reports 52-week acne drug trial results, plans U.S. study - Investing.com
Sagimet Biosciences details 56.7% acne response at 52 weeks - Mugglehead Investment Magazine
Sagimet Biosciences stock rises after pricing $115M securities offering - TradingView
About $115 million from a share sale is expected to help fund Sagimet's acne trial and other drug work. - Stock Titan
SGMT: Denifanstat achieved strong 52-week efficacy and safety, supporting advancement to U.S. Phase 3 trials - TradingView
A 240-patient open-label acne extension yields 52-week results for Sagimet (SGMT). - Stock Titan
Sagimet Biosciences Reports Positive 52-Week Phase 3 OLE Results for Denifanstat in Moderate to Severe Acne - Quiver Quantitative
Sagimet raised about $115 million, with an acne drug trial among its planned uses. - Stock Titan
Sagimet Biosciences Raises $115 Million in Stock Offering - Intellectia AI
Acne Vulgaris Market Set for Significant Growth During the Forecast Period (2026–2036), Amid Rising Disease Burden and Therapeutic Advances | DelveInsight - GlobeNewswire Inc.
H.C. Wainwright reiterates Sagimet stock rating on EADV data By Investing.com - Investing.com South Africa
H.C. Wainwright reiterates Sagimet stock rating on EADV data - Investing.com India
Sagimet to host event on denifanstat acne trial data Wednesday By Investing.com - Investing.com Nigeria
Sagimet to host event on denifanstat acne trial data Wednesday - Investing.com
Sagimet Biosciences to Host Virtual KOL Event, “Denifanstat - GlobeNewswire
Sagimet Biosciences (SGMT): Phase 3 Trial, FDA Path and Cash Runway Set Up Key Catalysts - Insider Monkey
Sagimet Biosciences Down Over 15%, on Pace for Largest Percent Decrease Since April 2025 -- Data Talk - Moomoo
United Therapeutics, Sagimet drop after Goldman Sachs Sell ratings - TradingView
Sagimet Biosciences (SGMT) Short Interest & Short Float | Updated Sep 2026 - MarketBeat
Sagimet Biosciences Inc. (SGMT) Options ChainYahoo Finance - Yahoo! Finance Canada
SGMT Stock Surged 40% And Breached 200-DMA For The First Time In Nearly 3 Months – What’s Got Retail Buzzing? - Stocktwits
Barclays upgrades Sagimet stock rating on acne drug potential By Investing.com - Investing.com Nigeria
Sagimet Biosciences at Cantor conference: acne drug push gains traction By Investing.com - Investing.com Canada
This Illumina Analyst Turns Bullish; Here Are Top 5 Upgrades For Wednesday - Benzinga
symbol__ Stock Quote Price and Forecast - CNN
Barclays Upgrades Sagimet Biosciences to Overweight From Equalweight, Adjusts Price Target to $18 From $8 - marketscreener.com
Barclays upgrades Sagimet stock rating on acne drug potential - investing.com
A drug developer's investor chat is set for Sept. 9 in New York - Stock Titan
Enterprise value to EBIT forward of Sagimet Biosciences Inc.Series A – NASDAQ:SGMT - TradingView
H.C. Wainwright Maintains Sagimet Biosciences(SGMT.US) With Buy Rating, Maintains Target Price $29 - Moomoo
Sagimet Biosciences Advances AURORA U.S. Phase 3 Trial Of Denifanstat In Acne Toward Patient Enrollment In Q4 2026 - TradingView
Sagimet plans to start acne drug trial enrollment in Q4 - Investing.com India
Sagimet plans to start acne drug trial enrollment in Q4 By Investing.com - Investing.com Canada
Sagimet (SGMT) Earnings Report: Profit Per Share Clears Its Benchmark in Latest Trading - vinanet.vn
Sagimet Biosciences Inc Azioni (SGMT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Sagimet Biosciences Inc Azioni (SGMT) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Kemble George | Director |
Aug 14 '26 |
Sale |
10.23 |
350,987 |
3,591,580 |
62,161 |
0.05%
0.82%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):